ClinicalTrials.gg
CompletedNCT02329327Updated Feb 16, 2022Results posted

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

A Phase 3 interventional study of Andexanet in Bleeding, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 87 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
479
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hemorrhage by AstraZeneca — none open to participants now, none under way, none of them phase 3. Hemorrhage · AstraZeneca.

Started
2015
with 1 other
Phase 3
4 of 12
none open now
Registered
6th of 12
by date

Among the 12 studies in Hemorrhage by AstraZeneca, this one is one of 2 that started in 2015, is one of 4 in phase 3, and was the 6th registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

None of the 12 studies in Hemorrhage by AstraZeneca is open now. The open studies under Hemorrhage, anywhere →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Hemorrhage by AstraZeneca as a file.
02

Study summary

The purpose of this study was to evaluate the hemostatic efficacy of andexanet alfa (andexanet) in participants receiving a factor Xa (FXa) inhibitor (apixaban, rivaroxaban, edoxaban, enoxaparin) who were experiencing an acute major bleed. The safety of andexanet was also studied.

03

Conditions studied

  • Bleeding

Browse trials for

Keywords

  • Factor Xa Inhibitors
  • Major
  • Bleeding
  • Anticoagulant
  • Major Bleeding
  • Andexanet Alfa
  • Reversal Agent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Acute major bleeding episode that required urgent reversal of anticoagulation; defined by at least one of the following:

    • Acute bleeding that was potentially life-threatening, or
    • Acute bleeding associated with a fall in level by ≥2 grams/deciliter (g/dL), or
    • Acute bleeding associated with a hemoglobin level of ≤8 g/dL if no baseline hemoglobin was available, or
    • Acute bleeding in a critical area or organ such as intraspinal, pericardial, or intracranial.
  2. If bleeding was intracranial or intraspinal, the participant must have undergone a head computed tomography (CT) or magnetic resonance imaging (MRI) scan demonstrating the bleeding.
  3. Participant received or was believed to have received one of the following within 18 hours prior to andexanet administration: apixaban, rivaroxaban, edoxaban, or enoxaparin.
  4. For participants with intracranial bleeding, there must be a reasonable expectation that andexanet treatment will commence within 2 hours of the baseline imaging evaluation.

Key Exclusion Criteria:

  1. The participant was scheduled to undergo surgery in less than 12 hours, with the exception of minimally invasive surgery/procedures.
  2. Participant with an intracerebral hemorrhage that had any of the following:

    • Glasgow coma score \<7, or
    • Intracerebral hematoma >60 cubic centimeters as assessed by CT or MRI
  3. Participants with visible, musculoskeletal or intra-articular bleeding as their qualifying bleed.
  4. Expected survival of less than 1 month.
  5. Recent history (within 2 weeks) of a diagnosed thrombotic event as follows: venous thromboembolism, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, , unstable angina pectoris hospitalization or severe peripheral vascular disease within 2 weeks prior to Screening.
  6. Severe sepsis or septic shock at the time of Screening.
  7. Pregnant or a lactating female.
  8. Participant received any of the following drugs or blood products within 7 days of Screening:

    • Vitamin K antagonist
    • Dabigatran
    • Prothrombin Complex Concentrate (PCC) products or recombinant factor VIIa (rfVIIa)
    • Whole blood, plasma fractions
  9. Treated with an drug \<30 days prior to Screening.
  10. Planned administration of PCC, fresh frozen plasma or rfVIIa from Screening until within 12 hours after the end of the andexanet infusion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
479 participants (actual)

Study arms

  • Experimental
    Andexanet

    Participants received andexanet as an intravenous bolus administered over \~15 to 30 minutes, followed immediately by a continuous infusion administered over \~120 minutes.

    Biological: Andexanet

Interventions

  • BiologicalAndexanet

    There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.

    Also known as: ALXN2070, Andexanet Alfa, PRT064445, Andexxa

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor

    Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. The change from baseline was calculated as the reduction in anti-fXa activity from baseline to the on-treatment nadir (that is, the minimum value between end of bolus and end of infusion). Percent reduction was calculated as the ratio between the maximum change from baseline and the baseline value, multiplied by 100.

    Time frame: Baseline, 12 Hours (post infusion)

  2. Participants Achieving Hemostatic Efficacy

    Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. These ratings were based on pre-specified criteria that were included in the EAC Charter. The EAC was blinded to anti-fXa activity levels. Participant results were classified as either success or failure based on the hemostatic efficacy rating (success = excellent/good, failure = poor/none). Participants rated by the EAC as non-evaluable due to administrative reasons were excluded from the analysis of hemostatic efficacy.

    Time frame: 12 Hours (post infusion)

Secondary outcomes

  1. Percent Change From Baseline In Anti-fXa Activity By Hemostatic Efficacy

    This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons.

    Time frame: Baseline, 12 Hours (post infusion)

07

Results

Posted Feb 16, 2022

Participant flow

Participant flow — Overall Study
MilestoneAndexanetAndexanet - Additional Participants
Started4772
Received at least 1 dose of study drug4772
Efficacy population3472
Death30
Completed3922
Not completed850
Withdrew: Death780
Withdrew: Withdrawal by subject30
Withdrew: Lost to follow-up40

Outcome measures

PrimaryPercent Change From Baseline In Anti-fXa Activity By FXa Inhibitor

Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. The change from baseline was calculated as the reduction in anti-fXa activity from baseline to the on-treatment nadir (that is, the minimum value between end of bolus and end of infusion). Percent reduction was calculated as the ratio between the maximum change from baseline and the baseline value, multiplied by 100.

Time frame:
Baseline, 12 Hours (post infusion)
Reported as:
Median · Percent Change
Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor
Percent ChangeFXa Inhibitor: ApixabanFXa Inhibitor: RivaroxabanFXa Inhibitor: EdoxabanFXa Inhibitor: EnoxaparinFXa Inhibitor: Rivaroxaban - Additional Participants
Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor-93.3 (-94.2 to -92.5)-94.1 (-95.1 to -93.0)-71.3 (-82.3 to -65.2)-75.41 (-79.17 to -66.67)-96.3 (-98.3 to -94.3)
PrimaryParticipants Achieving Hemostatic Efficacy

Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. These ratings were based on pre-specified criteria that were included in the EAC Charter. The EAC was blinded to anti-fXa activity levels. Participant results were classified as either success or failure based on the hemostatic efficacy rating (success = excellent/good, failure = poor/none). Participants rated by the EAC as non-evaluable due to administrative reasons were excluded from the analysis of hemostatic efficacy.

Time frame:
12 Hours (post infusion)
Reported as:
Count of participants · Participants
Participants Achieving Hemostatic Efficacy
ParticipantsFXa Inhibitor: ApixabanFXa Inhibitor: RivaroxabanFXa Inhibitor: EdoxabanFXa Inhibitor: EnoxaparinBleed Type: GastrointestinalBleed Type: Intracranial HemorrhageBleed Type: OtherAndexanet: Low DoseAndexanet: High DoseOverallFXa Inhibitor: Rivaroxaban - Additional ParticipantsBleed Type: Intracranial Hemorrhage - Additional ParticipantsAndexanet: Low Dose - Additional ParticipantAndexanet: High Dose - Additional Participant
Excellent/Good13410222146119318218542722211
Poor/None352562135145117680000
SecondaryPercent Change From Baseline In Anti-fXa Activity By Hemostatic Efficacy

This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons.

Time frame:
Baseline, 12 Hours (post infusion)
Reported as:
Median · Percent Change
Percent Change From Baseline In Anti-fXa Activity By Hemostatic Efficacy
Percent ChangeFXa Inhibitor: ApixabanFXa Inhibitor: RivaroxabanFXa Inhibitor: EdoxabanFXa Inhibitor: EnoxaparinFXa Inhibitor: Rivaroxaban - Additional Participants
Excellent/Good-93.4 (-94.3 to -92.6)-94.6 (-95.2 to -93.5)-75.8 (-84.4 to -65.2)-75.20 (-77.08 to -65.91)-96.3 (-98.3 to -94.3)
Poor/None-93.3 (-95.3 to -90.6)-92.4 (-96.5 to -85.0)-65.2 (-85.3 to 3.0)-78.44 (-82.46 to -74.42)—

Adverse events

Collected over Day 1 through Day 37.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Andexanet: Low Dose66/382 (17.3%)157/382 (41.1%)40/382 (10.5%)
Andexanet: High Dose15/97 (15.5%)43/97 (44.3%)8/97 (8.2%)
Most frequent serious events
Showing 10 of 149
Most frequent serious events
EventAndexanet: Low DoseAndexanet: High Dose
PneumoniaInfections and infestations14/3826/97
Cerebrovascular AccidentNervous system disorders4/3824/97
SepsisInfections and infestations4/3823/97
Cardiac FailureCardiac disorders3/3823/97
Respiratory FailureRespiratory, thoracic and mediastinal disorders10/3822/97
Ischaemic StrokeNervous system disorders8/3822/97
Cerebral InfarctionNervous system disorders3/3822/97
Neurological DecompensationNervous system disorders2/3822/97
Acute Myocardial InfarctionCardiac disorders3/3822/97
Myocardial InfarctionCardiac disorders3/3822/97
Most frequent other events
Most frequent other events
EventAndexanet: Low DoseAndexanet: High Dose
Urinary Tract InfectionInfections and infestations40/3828/97

Baseline characteristics

Safety Population: all participants who received any amount of andexanet.

Age, Continuous
Age, Continuous(years)AndexanetAndexanet - Additional ParticipantsTotal
Mean77.9 ± 10.6671.0 ± 11.3177.9 ± 10.66
Sex: Female, Male
Sex: Female, Male(Participants)AndexanetAndexanet - Additional ParticipantsTotal
Female2181219
Male2591260
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AndexanetAndexanet - Additional ParticipantsTotal
Hispanic or Latino16016
Not Hispanic or Latino4492451
Unknown or Not Reported12012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AndexanetAndexanet - Additional ParticipantsTotal
Race : White4140414
Race : Black or African American29029
Race : Other25227
Race : Missing909
Region of Enrollment
Region of Enrollment(participants)AndexanetAndexanet - Additional ParticipantsTotal
North America2120212
Europe2480248
Japan17219
FXa Inhibitor
FXa Inhibitor(Participants)AndexanetAndexanet - Additional ParticipantsTotal
Apixaban2450245
Rivaroxaban1742176
Edoxaban36036
Enoxaparin22022
Bleed Type
Bleed Type(Participants)AndexanetAndexanet - Additional ParticipantsTotal
Gastrointestinal1090109
Intracranial Hemorrhage3292331
Other39039
08

Study locations

87 sites
  • Clinical Study Site
    Long Beach, California, United States
  • Clinical Study Site
    Los Angeles, California, United States
  • Clinical Study Site
    Orange, California, United States
  • Clinical Study Site
    Fort Lauderdale, Florida, United States
  • Clinical Study Site
    Jacksonville, Florida, United States
  • Clinical Study Site
    Sarasota, Florida, United States
  • Clinical Study Site
    Tampa, Florida, United States
  • Clinical Study Site
    Annapolis, Maryland, United States
  • Clinical Study Site
    Boston, Massachusetts, United States
  • Clinical Study Site
    Detroit, Michigan, United States
  • Clinical Study Site
    Royal Oak, Michigan, United States
  • Clinical Study Site
    Troy, Michigan, United States
  • Clinical Study Site
    Saint Louis, Missouri, United States
  • Clinical Study Site
    Rochester, New York, United States
  • Clinical Study Site
    Asheville, North Carolina, United States
  • Clinical Study Site
    Chapel Hill, North Carolina, United States
  • Clinical Study Site
    Raleigh, North Carolina, United States
  • Clinical Study Site
    Cincinnati, Ohio, United States
  • Clinical Study Site
    Cleveland, Ohio, United States
  • Clinical Study Site
    Pittsburgh, Pennsylvania, United States
  • Clinical Study Site
    Austin, Texas, United States
  • Clinical Study Site
    Fort Worth, Texas, United States
  • Clinical Study Site
    Huntington, West Virginia, United States
  • Clinical Study Site
    Bruxelles, Belgium
  • Clinical Study Site
    Genk, Belgium
  • Clinical Study Site
    Leuven, Belgium
  • Clinical Study Site
    Hamilton, Ontario, Canada
  • Clinical Study Site
    Montreal, Quebec, Canada
  • Clinical Study Site
    Clermont-Ferrand, France
  • Clinical Study Site
    Grenoble, France
  • Clinical Study Site
    Limoges, France
  • Clinical Study Site
    Lyon, France
  • Clinical Study Site
    Poitiers, France
  • Clinical Study Site
    Altenburg, Germany
  • Clinical Study Site
    Augsburg, Germany
  • Clinical Study Site
    Berlin, Germany
  • Clinical Study Site
    Bremen, Germany
  • Clinical Study Site
    Celle, Germany
  • Clinical Study Site
    Chemnitz, Germany
  • Clinical Study Site
    Coburg, Germany
  • Clinical Study Site
    Detmold, Germany
  • Clinical Study Site
    Dresden, Germany
  • Clinical Study Site
    Essen, Germany
  • Clinical Study Site
    Greifswald, Germany
  • Clinical Study Site
    Göttingen, Germany
  • Clinical Study Site
    Halle, Germany
  • Clinical Study Site
    Hamburg, Germany
  • Clinical Study Site
    Hannover, Germany
  • Clinical Study Site
    Heidelberg, Germany
  • Clinical Study Site
    Hessen, Germany
  • Clinical Study Site
    Jena, Germany
  • Clinical Study Site
    Konstanz, Germany
  • Clinical Study Site
    Leipzig, Germany
  • Clinical Study Site
    Lubeck, Germany
  • Clinical Study Site
    Ludwigshafen, Germany
  • Clinical Study Site
    Mainz, Germany
  • Clinical Study Site
    Minden, Germany
  • Clinical Study Site
    Munich, Germany
  • Clinical Study Site
    Münster, Germany
  • Clinical Study Site
    Osnabrück, Germany
  • Clinical Study Site
    Regensburg, Germany
  • Clinical Study Site
    Sande, Germany
  • Clinical Study Site
    Trier, Germany
  • Clinical Study Site
    Tübingen, Germany
  • Clinical Study Site
    Ulm, Germany
  • Clinical Study Site
    Würzburg, Germany
  • Clinical Study Site
    Fukuoka, Japan
  • Clinical Study Site
    Gunma, Japan
  • Clinical Study Site
    Hiroshima, Japan
  • Clinical Study Site
    Ibaraki, Japan
  • Clinical Study Site
    Izumisano, Japan
  • Clinical Study Site
    Kobe, Japan
  • Clinical Study Site
    Kumamoto, Japan
  • Clinical Study Site
    Nagoya, Japan
  • Clinical Study Site
    Sendai, Japan
  • Clinical Study Site
    Shiwa-gun, Japan
  • Clinical Study Site
    Suita, Japan
  • Clinical Study Site
    Tokyo, Japan
  • Clinical Study Site
    Yamaguchi, Japan
  • Clinical Study Site
    Yokosuka, Japan
  • Clinical Study Site
    Amsterdam, Netherlands
  • Clinical Study Site
    Barcelona, Spain
  • Clinical Study Site
    Caceres, Spain
  • Clinical Study Site
    Madrid, Spain
  • Clinical Study Site
    Cardiff, United Kingdom
  • Clinical Study Site
    London, United Kingdom
  • Clinical Study Site
    Stoke on Trent, United Kingdom
09

References and documents

Publications

  • Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016 Sep 22;375(12):1131-41. doi: 10.1056/NEJMoa1607887. Epub 2016 Aug 30. PubMed 27573206 ↗
  • Birocchi S, Fiorelli EM, Podda GM. Andexanet Alfa for Factor Xa Inhibitor Reversal. N Engl J Med. 2016 Dec 22;375(25):2498-9. doi: 10.1056/NEJMc1613270. No abstract available. PubMed 28009495 ↗
  • Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019 Apr 4;380(14):1326-1335. doi: 10.1056/NEJMoa1814051. Epub 2019 Feb 7. PubMed 30730782 ↗
  • Costa OS, Connolly SJ, Sharma M, Beyer-Westendorf J, Christoph MJ, Lovelace B, Coleman CI. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care. 2022 Jun 16;26(1):180. doi: 10.1186/s13054-022-04043-8. PubMed 35710578 ↗
  • Huttner HB, Gerner ST, Kuramatsu JB, Connolly SJ, Beyer-Westendorf J, Demchuk AM, Middeldorp S, Zotova E, Altevers J, Andersohn F, Christoph MJ, Yue P, Stross L, Schwab S. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. Stroke. 2022 Feb;53(2):532-543. doi: 10.1161/STROKEAHA.121.034572. Epub 2021 Oct 14. PubMed 34645283 ↗
  • Demchuk AM, Yue P, Zotova E, Nakamya J, Xu L, Milling TJ Jr, Ohara T, Goldstein JN, Middeldorp S, Verhamme P, Lopez-Sendon JL, Conley PB, Curnutte JT, Eikelboom JW, Crowther M, Connolly SJ; ANNEXA-4 Investigators. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke. 2021 Jun;52(6):2096-2105. doi: 10.1161/STROKEAHA.120.030565. Epub 2021 May 10. Erratum In: Stroke. 2021 Aug;52(8):e525. doi: 10.1161/STR.0000000000000386. PubMed 33966491 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Sep 2020, 65 months.

Results were first posted in Feb 2022, 1 year 4 months after primary completion. A results delay was requested in Sep 2021.

Of 72 phase 3 interventional studies under Hemorrhage, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 65 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2014
First posted
Dec 31, 2014
StartActual
Apr 10, 2015
Primary completionActual
Sep 24, 2020
CompletionActual
Sep 24, 2020
Results delay requested
Sep 24, 2021
Results first posted
Feb 16, 2022
Last update
Feb 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02329327
Collaborators
Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals), Population Health Research Institute
Responsible party
Sponsor
First posted
Dec 31, 2014
Start date
Apr 10, 2015
Primary completion
Sep 24, 2020
Completion
Sep 24, 2020
Results posted
Feb 16, 2022
Last update
Feb 16, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PRT064445

Start the discussion